Commentary: The North West London Clinical Trials Alliance: efficiency and innovation in clinical trial delivery.
COVID-19
Clinical Trials Alliance
Clinical trials
Digital tools
Diversity
Efficiency
Equity
Inclusivity
Participant recruitment
Public health
Vaccine trials
and Inclusion (EDI)
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
15
04
2024
accepted:
14
07
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
28
7
2024
Statut:
epublish
Résumé
The set-up, activation, and delivery of clinical trials is pivotal for the advancement of medical science, serving as the primary mechanism through which new therapeutic interventions are validated for clinical use. Despite their critical role, the execution of these trials is often encumbered by a multitude of challenges. The North West London Clinical Trials Alliance (The Alliance) was established to address these complexities. It aims to bridge the gap between emerging scientific research and its clinical application through strategic collaborations among healthcare and research entities, thereby enhancing the regional ecosystem for clinical trials. This commentary aims to offer clarity on the fundamental insights that underlie The Alliance, providing a comprehensive understanding of its operational structure and the ecosystem it has fostered to optimise clinical trial delivery and revenue generation. The strategy employed by The Alliance centres on the cultivation of strategic partnerships across a broad spectrum of stakeholders. This approach addresses key operational challenges in clinical trial management, facilitating improvements in the development, setup, activation, and recruitment stages. Notably, The Alliance has reduced the average time to initiate trials to 19 days, compared to the standard 75 days typically observed for commercial setups in North West London. The effectiveness of The Alliance's framework was notably demonstrated during the COVID-19 pandemic, particularly with the expedited recruitment performance in the Janssen COVID-19 vaccine study conducted at Charing Cross Hospital. This instance highlighted the Alliance's capability to meet and exceed recruitment targets promptly while maintaining diversity within study cohorts. Additionally, The Alliance has effectively harnessed digital technology and infrastructure, enhancing its attractiveness to commercially funded studies and illustrating a sustainable model for clinical trial financing and execution. The North West London Clinical Trials Alliance represents a strategic response to the conventional challenges faced in clinical trial management, emphasising the importance of cross-sectoral collaboration and resource optimisation. Its efforts, particularly highlighted by its response to the COVID-19 pandemic, provide a case study in enhancing trial delivery and efficiency with significant implications for both regional and global clinical trials research communities.
Sections du résumé
BACKGROUND
BACKGROUND
The set-up, activation, and delivery of clinical trials is pivotal for the advancement of medical science, serving as the primary mechanism through which new therapeutic interventions are validated for clinical use. Despite their critical role, the execution of these trials is often encumbered by a multitude of challenges. The North West London Clinical Trials Alliance (The Alliance) was established to address these complexities. It aims to bridge the gap between emerging scientific research and its clinical application through strategic collaborations among healthcare and research entities, thereby enhancing the regional ecosystem for clinical trials.
MAIN TEXT
METHODS
This commentary aims to offer clarity on the fundamental insights that underlie The Alliance, providing a comprehensive understanding of its operational structure and the ecosystem it has fostered to optimise clinical trial delivery and revenue generation. The strategy employed by The Alliance centres on the cultivation of strategic partnerships across a broad spectrum of stakeholders. This approach addresses key operational challenges in clinical trial management, facilitating improvements in the development, setup, activation, and recruitment stages. Notably, The Alliance has reduced the average time to initiate trials to 19 days, compared to the standard 75 days typically observed for commercial setups in North West London. The effectiveness of The Alliance's framework was notably demonstrated during the COVID-19 pandemic, particularly with the expedited recruitment performance in the Janssen COVID-19 vaccine study conducted at Charing Cross Hospital. This instance highlighted the Alliance's capability to meet and exceed recruitment targets promptly while maintaining diversity within study cohorts. Additionally, The Alliance has effectively harnessed digital technology and infrastructure, enhancing its attractiveness to commercially funded studies and illustrating a sustainable model for clinical trial financing and execution.
CONCLUSION
CONCLUSIONS
The North West London Clinical Trials Alliance represents a strategic response to the conventional challenges faced in clinical trial management, emphasising the importance of cross-sectoral collaboration and resource optimisation. Its efforts, particularly highlighted by its response to the COVID-19 pandemic, provide a case study in enhancing trial delivery and efficiency with significant implications for both regional and global clinical trials research communities.
Identifiants
pubmed: 39069627
doi: 10.1186/s13063-024-08344-x
pii: 10.1186/s13063-024-08344-x
doi:
Types de publication
Journal Article
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
509Informations de copyright
© 2024. The Author(s).
Références
Huang GD, Bull J, Johnston McKee K, Mahon E, Harper B, Roberts JN. Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative. Contemp Clin Trials. 2018;66:74–9.
doi: 10.1016/j.cct.2018.01.003
pubmed: 29330082
Lai J, Forney L, Brinton DL, Simpson KN. Drivers of start-up delays in global randomized clinical trials. Therapeutic Innovation & Regulatory Science. 2021;55:212–27.
doi: 10.1007/s43441-020-00207-2
Kelly D, Spreafico A, Siu LL. Increasing operational and scientific efficiency in clinical trials. Br J Cancer. 2020;123:1207–8.
doi: 10.1038/s41416-020-0990-8
pubmed: 32690866
pmcid: 7555462
Chaudhari N, Ravi R, Gogtay NJ, Thatte UM. Recruitment and retention of the participants in clinical trials: challenges and solutions. Perspect Clin Res. 2020;11:64–9.
doi: 10.4103/picr.PICR_206_19
pubmed: 32670830
pmcid: 7342338
Kearney A, McKay A, Hickey H, Balabanova S, Marson AG, Gamble C, Williamson P. Opening research sites in multicentre clinical trials within the UK: a detailed analysis of delays. BMJ Open. 2014;4(9):e005874.
doi: 10.1136/bmjopen-2014-005874
pubmed: 25227630
pmcid: 4166133
Eichler HG, Sweeney F. The evolution of clinical trials: can we address the challenges of the future? Clin Trials. 2018;15:27–32.
doi: 10.1177/1740774518755058
pubmed: 29452522
Bieske L, Zinner M, Dahlhausen F, Trübel HKF. Critical path activities in clinical trial setup and conduct: how to avoid bottlenecks and accelerate clinical trials. Drug Discov Today. 2023;28:103733.
doi: 10.1016/j.drudis.2023.103733
pubmed: 37544639
Olver IN, Keech AC. Forming networks for research: proposal for an Australian clinical trials alliance. Med J Aust. 2013;198:198.
doi: 10.5694/mja12.11067
Okada K, Sengoku S. Entry into new therapeutic areas: the effect of alliance on clinical trials. Therapeutic Innovation & Regulatory Science. 2019;53(5):648–53.
doi: 10.1177/2168479018811829
Berkowitz JL, Fernández AO, Dichmann R, Kennedy KA, DiCarlo BA. Clinical trials networks and enrollment of historically underrepresented populations in medical oncology trials. J Clin Oncol. 2016;27(15_suppl):e20598.
doi: 10.1200/jco.2009.27.15_suppl.e20598
Gao X, Wen J, Song J. Capacity allocation and revenue sharing in healthcare alliances. Flex Serv Manuf J. 2020;32:829–51.
Imperial College Healthcare NHS Trust. Annual report 2020/21. Imperial College Healthcare NHS Trust. 2021. Available at https://www.england.nhs.uk/wp-content/uploads/2022/09/imperial-college-healthcare-nhs-trust-ara-20-21.pdf .
North West London Clinical Trials Alliance impact report. NIHR Clinical Research Network North West London; 2022.
Bell-Syer SEM, Thorpe LN, Thomas K, MacPherson H. GP participation and recruitment of patients to RCTs: lessons from trials of acupuncture and exercise for low back pain in primary care. Evidence-Based Complementary and Alternative Medicine. 2011;2011:687349.
doi: 10.1093/ecam/nen044
pubmed: 18955352
Bentley C, Cressman S, van der Hoek K, Arts K, Dancey J, Peacock S. Conducting clinical trials—costs, impacts, and the value of clinical trials networks: a scoping review. Clin Trials. 2019;16(2):183–93.
doi: 10.1177/1740774518820060
pubmed: 30628466